Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Mar 22;13(3):e0194733.
doi: 10.1371/journal.pone.0194733. eCollection 2018.

The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis

Fang Liu  1 , Tao Jin  2 , Lei Liu  1 , Zhongzheng Xiang  1 , Ruonan Yan  1 , Hui Yang  3
Affiliations
Meta-Analysis

The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis

Fang Liu et al. PLoS One. .

Abstract

Objectives: To compare clinical outcomes of concurrent chemoradiotherapy (CCRT) with those of radiotherapy alone for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy (IMRT) era.

Materials and methods: We comprehensively searched PubMed, Embase, and the Cochrane Library to identify eligible studies. Overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional recurrence-free survival (LRRFS) with hazard ratios (HRs), and toxicities with odd ratios (ORs) were analyzed.

Results: A total of seven studies met the criteria, with 1302 patients who were treated with IMRT alone or IMRT plus concurrent chemotherapy. No significant survival benefit was shown by CCRT regardless of OS (HR = 1.17, 95% CI 0.73-1.89, P = 0.508), PFS (HR = 0.76, 95% CI 0.38-1.50, P = 0.430), DMFS (HR = 0.89, 95% CI 0.33-2.41, P = 0.816), or LRRFS (HR = 1.03, 95% CI 0.95-1.12, P = 0.498). Additionally, CCRT notably increased the risk of acute grade 3-4 leukopenia (OR = 4.432, 95% CI 2.195-8.952, P < 0.001), compared to IMRT alone.

Conclusion: Adding concurrent chemotherapy to IMRT led to no survival benefit and increased acute toxicity reactions for stage II nasopharyngeal carcinoma.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow chart showing inclusion and exclusion of trials.
Fig 2
Fig 2. Forest plot and meta-analysis of OS (A) and LRRFS (B).
Fig 3
Fig 3. Forest plot and meta-analysis of DMFS (A) and PFS (B).
Fig 4
Fig 4. Egger’s tests for possible publication bias of OS (A), PFS (B), DMFS (C), LRRFS (D).
See this image and copyright information in PMC

References

    1. Cao S-M, Simons MJ, Qian C-N. The prevalence and prevention of nasopharyngeal carcinoma in China. Chinese Journal of Cancer. 2011;30(2):114–9. doi: 10.5732/cjc.010.10377 - DOI - PMC - PubMed
    1. Chang ET, Adami HO. The Enigmatic Epidemiology of Nasopharyngeal Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 2006;15(10):1765–77. doi: 10.1158/1055-9965.EPI-06-0353 - DOI - PubMed
    1. Chan AT, Gregoire V, Lefebvre JL, Licitra L, Hui EP, Leung SF, et al. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii83–5. Epub 2012/11/20. doi: 10.1093/annonc/mds266 . - DOI - PubMed
    1. NCCN Guidelines Version 2.2017 Head and Neck Cancers. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.
    1. Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, et al. Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial. Journal of the National Cancer Institute. 2011;103(23):1761–70. doi: 10.1093/jnci/djr432 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources